Nucleoplasmin-3 (NPM3)

Nucleoplasmin-3 (NPM3) is a nuclear chaperone protein and a member of the nucleophosmin/nucleoplasmin family, closely related to the more well-studied NPM1 and NPM2 proteins[1][2][3][4][5]. NPM3 is mainly localized in the nucleus, particularly the nucleolus, and is widely expressed in many cell types[1][2][3][4]. It plays important roles in chromatin remodeling, ribosomal RNA biogenesis, and possibly in chromatin assembly and other nuclear processes[1][2][3][5]. NPM3 can modulate the activity of other chaperones in the family, particularly NPM1, affecting functions such as histone chaperoning and ribosome biogenesis[1][3]. While NPM1 is a prominent oncogenic/loss-of-function target in human cancers (especially acute myeloid leukemia), NPM3 itself has not been established as a direct therapeutic target or as a clinically actionable biomarker[1][3][4][5]. There are no known drugs that directly target or modulate NPM3 specifically, and it is not considered a receptor, enzyme, or classic therapeutic target in pharmacology. NPM3's disease association is primarily through its roles in cell proliferation and fundamental nuclear processes, and there is some association with specific cancers (ex: lung papillary adenocarcinoma), but insufficient evidence to classify it as a major cancer driver or direct pharmacological target[1]. Though frequently listed with various aliases and listed in some databases for target identification, NPM3 does not currently meet the criteria for a druggable or actionable target. There are no reported interacting drugs, no mechanism of action citations for such, and no described use as a biomarker or source of safety concerns. Its molecular classification is best described as a nuclear chaperone involved in chromatin dynamics and ribosomal biogenesis[1][3][4][5].

Other names

Nucleoplasmin-3NPM3PORMINTMEM123nucleophosmin/nucleoplasmin family member 3